

TB Alliance Pipeline

March 2012

New Drug Discovery						
TARGET OR CELL- BASED SCREENING	LEAD IDENTIFICATION	LEAD OPTIMIZATION				
Natural Products IMCAS	Whole-Cell Hit to Lead Program GSK	Mycobacterial Gyrase Inhibitors GSK				
TB Drug Discovery Portfolio NITD		THPP Series GSK				
Topoisomerase I Inhibitors <i>AZ/NYMC</i>	Gyrase B Inhibitors AZ	Pyrazinamide Analogs Yonsei				
	Folate Biosynthesis Inhibitors AZ	Diarylquinolines Tibotec/U. of Auckland				
	Whole-Cell Hit to Lead Program <i>AZ</i>	Riminophenazines IMM/BTTTRI				
	RNA Polymerase Inhibitors <i>AZ</i>					
	Energy Metabolism Inhibitors AZ/U. Penn					

Development		
A-354		
U. of Auckl/ U. III		
icago		
eclinical TB		
gimen Testing		
rifampicin		
isoniazid		
pyrazinamide		
moxifloxacin		
PA-824		
TMC207		
linezolid		
clofazamine		
rifapentine		
PNU-100480		
U/U. III Chicago		

Clinical Development		Regimen Development		
Clinical Phase I		Clinical Phase II	Clinical Phase III	
	New Drugs		Moxifloxacin (+ H, R, Z) Bayer Enrollment completed	
	New		Moxifloxacin (+ R, Z, E) Bayer Enrollment completed	
	Novel Regimens	TMC207/PA-824/ Pyrazinamide PA-824/Pyrazinamide/ Moxifloxacin		
	Regimen Building Blocks	TMC207 /Pyrazinamide PA-824/Pyrazinamide		

Our R&D Partners							
AZ	AstraZeneca		NITD	Novartis Institute for Tropical Diseases			
Bayer	Bayer Healthcare AG		Novartis	Novartis Pharmaceutical			
BTTTRI	Beijing Tuberculosis and Thoracic Tumor Research Institute		NYMC	New York Medical College			
GSK	GlaxoSmithKline		Tibotec	Johnson & Johnson / Tibotec			
IMCAS	Institute of Microbiology, Chinese Academy of Sciences		U. of Auck	University of Auckland			
IMM	Institute of Materia Medica		U. Penn	University of Pennsylvania School of Medicine			
JHU	Johns Hopkins University		Yonsei	Yonsei University			

Novel TB regimen development